title: HLA ligandome tumor antigen discovery for personalized vaccine approach.
abstract: Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usually not used in the adult organism. The search for cancer-associated antigens shared by many patients with a particular cancer has yielded a number of hits used in clinical vaccination trials with indication of survival benefit. Targeting cancer-specific antigens, which are exclusively expressed on cancer cells and not on normal cells, holds the promise for much better results and perhaps even a cure. Such antigens, however, may specifically appear in very few patients or may be mutated appearing just in one patient. Therefore, to target these in a molecularly defined way, the approach has to be individualized.
authors.affiliation: Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany.
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Rammensee
authors.forename: Harpreet
authors.initials: H
authors.lastname: Singh-Jasuja
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism*; D019496:Cancer Vaccines / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010750:Phosphoproteins / Q000378:metabolism*; D057285:Precision Medicine / Q000379:methods*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C574674:La protein, human; D010750:Phosphoproteins